BioMarin Pharmaceutical (BMRN) 10-Q 28 Oct 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Oct. 25, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	000-26727
Entity Registrant Name	BioMarin Pharmaceutical Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	68-0397820
Entity Address, Address Line One	770 Lindaro Street
Entity Address, City or Town	San Rafael
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94901
City Area Code	415
Local Phone Number	506-6700
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	BMRN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		185,848,915
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001048477
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	[1]
Current assets:
Cash and cash equivalents	$ 761,515	$ 587,276
Short-term investments	512,253	426,599
Accounts receivable, net	419,622	373,399
Inventory	839,460	776,669
Other current assets	149,851	110,442
Total current assets	2,682,701	2,274,385
Noncurrent assets:
Long-term investments	372,302	507,793
Property, plant and equipment, net	1,051,821	1,035,461
Intangible assets, net	354,024	388,652
Goodwill	196,199	196,199
Deferred tax assets	1,455,205	1,450,161
Other assets	151,788	152,121
Total assets	6,264,040	6,004,772
Current liabilities:
Accounts payable and accrued liabilities	492,717	498,265
Short-term contingent consideration	28,303	48,232
Total current liabilities	521,020	546,497
Noncurrent liabilities:
Long-term convertible debt, net	1,082,033	1,079,077
Long-term contingent consideration	0	15,167
Other long-term liabilities	92,473	98,361
Total liabilities	1,695,526	1,739,102
Stockholders’ equity:
Common stock, $0.001 par value: 500,000,000 shares authorized; 185,824,253 and 183,912,514 shares issued and outstanding, respectively	186	184
Additional paid-in capital	5,335,853	5,191,502
Company common stock held by the Nonqualified Deferred Compensation Plan	(9,325)	(9,689)
Accumulated other comprehensive income	30,749	14,432
Accumulated deficit	(788,949)	(930,759)
Total stockholders’ equity	4,568,514	4,265,670
Total liabilities and stockholders’ equity	$ 6,264,040	$ 6,004,772
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	185,824,253	183,912,514
Common stock, shares outstanding (in shares)	185,824,253	183,912,514

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
REVENUES:
Total revenues	$ 505,344	$ 408,742	$ 1,558,501	$ 1,396,465
OPERATING EXPENSES:
Cost of sales	116,288	103,537	356,379	350,765
Research and development	157,829	157,869	476,855	467,701
Selling, general and administrative	216,816	183,333	608,270	541,812
Intangible asset amortization and contingent consideration	16,828	17,222	50,935	52,648
Gain on sale of nonfinancial assets, net	0	0	(108,000)	0
Total operating expenses	507,761	461,961	1,384,439	1,412,926
INCOME (LOSS) FROM OPERATIONS	(2,417)	(53,219)	174,062	(16,461)
Interest income	4,999	1,827	9,324	8,737
Interest expense	(4,679)	(3,870)	(12,344)	(11,491)
Other income (expense), net	193	9,102	(3,908)	10,439
INCOME (LOSS) BEFORE INCOME TAXES	(1,904)	(46,160)	167,134	(8,776)
Provision for (benefit from) income taxes	4,748	(9,666)	25,324	(2,594)
NET INCOME (LOSS)	$ (6,652)	$ (36,494)	$ 141,810	$ (6,182)
NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share)	$ (0.04)	$ (0.20)	$ 0.77	$ (0.03)
NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share)	$ (0.04)	$ (0.20)	$ 0.75	$ (0.03)
Weighted average common shares outstanding, basic (in shares)	185,597	183,214	185,009	182,616
Weighted average common shares outstanding, diluted (in shares)	185,597	183,214	192,252	182,616
COMPREHENSIVE INCOME (LOSS)	$ 5,625	$ (25,316)	$ 158,127	$ 20,196
Net product revenues
REVENUES:
Total revenues	493,348	393,840	1,516,533	1,348,279
Royalty and other revenues
REVENUES:
Total revenues	$ 11,996	$ 14,902	$ 41,968	$ 48,186

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands		Total		Previously Reported		Revision of Prior Period, Error Correction, Adjustment	Common Stock		Additional Paid-in Capital		Company Stock Held By NQDC		Accumulated other comprehensive income (loss)		Accumulated Deficit		Accumulated Deficit Previously Reported		Accumulated Deficit Revision of Prior Period, Error Correction, Adjustment
Beginning balance (in shares) at Dec. 31, 2020	[1]						181,741,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans (in shares)							1,827,000
Ending balance (in shares) at Sep. 30, 2021							183,568,000
Beginning balance at Dec. 31, 2020		$ 4,100,931		$ 4,106,002	[1]	$ (5,071)	$ 182	[1]	$ 4,993,407	[1]	$ (9,839)	[1]	$ (16,139)	[1]	$ (866,680)	[1]	$ (861,609)	[1]	$ (5,071)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans, net of tax							2		(11,551)
Stock-based compensation									151,500
Common stock held by the Nonqualified Deferred Compensation Plan (the NQDC)									386		(386)
Other comprehensive income (loss)													26,378
Net income (loss)		(6,182)													(6,182)
Ending balance at Sep. 30, 2021		4,261,078					$ 184		5,133,742		(10,225)		10,239		(872,862)
Beginning balance (in shares) at Jun. 30, 2021							183,322,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans (in shares)							246,000
Ending balance (in shares) at Sep. 30, 2021							183,568,000
Beginning balance at Jun. 30, 2021		4,236,500		4,241,571		(5,071)	$ 183		5,083,831		(10,207)		(939)		(836,368)		(831,297)		(5,071)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans, net of tax							1		(460)
Stock-based compensation									50,353
Common stock held by the Nonqualified Deferred Compensation Plan (the NQDC)									18		(18)
Other comprehensive income (loss)													11,178
Net income (loss)		(36,494)													(36,494)
Ending balance at Sep. 30, 2021		$ 4,261,078					$ 184		5,133,742		(10,225)		10,239		(872,862)
Beginning balance (in shares) at Dec. 31, 2021		183,912,514					183,913,000	[1]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans (in shares)							1,912,000
Ending balance (in shares) at Sep. 30, 2022		185,824,253					185,825,000
Beginning balance at Dec. 31, 2021		$ 4,265,670	[2]	4,270,741	[1]	(5,071)	$ 184	[1]	5,191,502	[1]	(9,689)	[1]	14,432	[1]	(930,759)	[1]	(925,688)	[1]	(5,071)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans, net of tax							2		(8,306)
Stock-based compensation									153,021
Common stock held by the Nonqualified Deferred Compensation Plan (the NQDC)									(364)		364
Other comprehensive income (loss)													16,317
Net income (loss)		141,810													141,810
Ending balance at Sep. 30, 2022		$ 4,568,514					$ 186		5,335,853		(9,325)		30,749		(788,949)
Beginning balance (in shares) at Jun. 30, 2022							185,453,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans (in shares)							372,000
Ending balance (in shares) at Sep. 30, 2022		185,824,253					185,825,000
Beginning balance at Jun. 30, 2022		$ 4,499,737		$ 4,504,808		$ (5,071)	$ 186		5,272,666		(9,290)		18,472		(782,297)		$ (777,226)		$ (5,071)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuances under equity incentive plans, net of tax							0		6,847
Stock-based compensation									56,305
Common stock held by the Nonqualified Deferred Compensation Plan (the NQDC)									35		(35)
Other comprehensive income (loss)													12,277
Net income (loss)		(6,652)													(6,652)
Ending balance at Sep. 30, 2022		$ 4,568,514					$ 186		$ 5,335,853		$ (9,325)		$ 30,749		$ (788,949)
[1]The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 25, 2022, except for the beginning balances of Accumulated Deficit and Total Stockholders’ Equity for the three and nine-month periods which have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.[2] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 141,810	$ (6,182)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	77,416	82,053
Non-cash interest expense	3,089	3,114
Amortization of premium on investments	3,741	3,279
Stock-based compensation	149,574	153,372
Gain on sale of nonfinancial assets, net	(108,000)	0
Deferred income taxes	(743)	(12,020)
Unrealized foreign exchange gain	(16,075)	(1,347)
Non-cash changes in the fair value of contingent consideration	2,243	6,254
Other	(700)	(1,317)
Changes in operating assets and liabilities:
Accounts receivable, net	(53,752)	65,513
Inventory	(27,419)	(19,125)
Other current assets	(8,558)	27,029
Other assets	12,140	(407)
Accounts payable and other short-term liabilities	(2,398)	(7,129)
Other long-term liabilities	(3,252)	269
Net cash provided by operating activities	169,116	293,356
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(85,271)	(66,840)
Maturities and sales of investments	477,244	502,112
Purchases of investments	(457,382)	(737,144)
Proceeds from sale of nonfinancial assets	110,000	0
Purchase of intangible assets	(9,910)	(8,026)
Other	0	(994)
Net cash provided by (used in) investing activities	34,681	(310,892)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of awards under equity incentive plans	43,866	32,877
Taxes paid related to net share settlement of equity awards	(50,696)	(44,428)
Payment of contingent consideration	(21,054)	0
Principal repayments of financing leases	(1,635)	(2,492)
Other	0	(401)
Net cash used in financing activities	(29,519)	(14,444)
Effect of exchange rate changes on cash	(39)	(35)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	174,239	(32,015)
Cash and cash equivalents:
Beginning of period	587,276	649,158
End of period	761,515	617,143
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid for income taxes	13,425	15,531
Cash paid for interest	6,575	6,673
SUPPLEMENTAL CASH FLOW DISCLOSURES FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:
Decrease in accounts payable and accrued liabilities related to fixed assets	(5,240)	(7,690)
Increase (decrease) in accounts payable and accrued liabilities related to intangible assets	$ (224)	$ 9,386

BUSINESS OVERVIEW AND SIGNIFICA

BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES	BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES Nature of Operations BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of eight commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. ROCTAVIAN (formerly known as valoctocogene roxaparvovec) was granted conditional marketing approval in the European Union (EU) on August 24, 2022. Basis of Presentation The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022 or any other period. Use of Estimates U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the COVID-19 pandemic could continue to directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods. Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements except for the transaction disclosed in Note 12 to these Condensed Consolidated Financial Statements. Correction of Immaterial Error During the three months ended September 30, 2022, the Company became aware of an unrecorded amount due to a third party following the January 2020 sale of the worldwide rights of Firdapse, the Company's commercial product for the treatment of Lambert-Eaton myasthenic syndrome. The Company evaluated the materiality of the previously described error from a qualitative and quantitative perspective. Based on such evaluation, the Company concluded that the error was not material to any individual current or prior period, nor did it have an effect on the Company’s trend of financial results, taking into account the requirements of the SEC Staff Accounting Bulletin No. 108, C onsidering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements . Although the effect of the error was not material to the current or previously issued financial statements, the Company has corrected the accompanying Condensed Consolidated Balance Sheet and Statements of Stockholders Equity. The correction increased the fiscal year 2021 beginning balance of Accumulated Deficit and decreased Total Stockholders’ Equity by $5.1 million, and had the following impact on certain December 31, 2021 balances: an increase to Accounts Payable and Accrued Liabilities of $6.7 million, an increase to Deferred Tax Assets of $1.1 million, an increase to Other Assets of $0.4 million and a decrease to Other Long-term Liabilities of $0.1 million. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2022, as compared to the significant accounting policies disclosed in Note 1 – Business Overview and Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Recent Accounting Pronouncements There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the nine months ended September 30, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, that the Company believes are of significance or potential significance to the Company.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
FINANCIAL INSTRUMENTS	FINANCIAL INSTRUMENTS All marketable securities were classified as available-for-sale at September 30, 2022 and December 31, 2021. The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented: September 30, 2022 Amortized Cost Gross Gross Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash $ 358,325 $ — $ — $ 358,325 $ 358,325 $ — $ — Level 2: Money market instruments 347,274 — — 347,274 347,274 — — Corporate debt securities 522,723 10 (14,622) 508,111 978 273,333 233,800 U.S. government agency securities 354,810 4 (4,377) 350,437 54,938 209,469 86,030 Commercial paper 29,461 1 (22) 29,440 — 29,440 — Asset-backed securities 53,182 — (699) 52,483 — 11 52,472 Subtotal 1,307,450 15 (19,720) 1,287,745 403,190 512,253 372,302 Total $ 1,665,775 $ 15 $ (19,720) $ 1,646,070 $ 761,515 $ 512,253 $ 372,302 December 31, 2021 Amortized Cost Gross Gross Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash $ 301,177 $ — $ — $ 301,177 $ 301,177 $ — $ — Level 2: Money market instruments 285,099 — — 285,099 285,099 — — Corporate debt securities 584,000 386 (2,086) 582,300 — 200,304 381,996 U.S. government agency securities 224,774 182 (325) 224,631 — 146,421 78,210 Commercial paper 68,384 — — 68,384 1,000 67,384 — Asset-backed securities 56,936 10 (95) 56,851 — 9,451 47,400 Foreign and other 3,097 141 (12) 3,226 — 3,039 187 Subtotal 1,222,290 719 (2,518) 1,220,491 286,099 426,599 507,793 Total $ 1,523,467 $ 719 $ (2,518) $ 1,521,668 $ 587,276 $ 426,599 $ 507,793 (1) The Company’s short-term marketable securities mature in one year or less. (2) The Company’s long-term marketable securities mature between one As of September 30, 2022, the Company had the ability and intent to hold all investments that were in an unrealized loss position until maturity. The Company considered its intent and ability to hold the securities until recovery of amortized cost basis, the extent to which fair value is less than amortized cost basis, conditions specifically related to the security’s industry and geography, payment structure and history and changes to the ratings (if any) in determining that the decline in fair value compared to carrying value is not related to a credit loss.

SUPPLEMENTAL FINANCIAL STATEMEN

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION	SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION Supplemental Balance Sheet Information Inventory consisted of the following: September 30, December 31, Raw materials $ 109,480 $ 80,269 Work-in-process 425,505 415,261 Finished goods 304,475 281,139 Total inventory $ 839,460 $ 776,669 Property, Plant and Equipment, Net consisted of the following: September 30, December 31, Property, plant and equipment, gross $ 1,834,220 $ 1,756,035 Accumulated depreciation (782,399) (720,574) Total property, plant and equipment, net $ 1,051,821 $ 1,035,461 Depreciation expense, net of amounts capitalized into inventory, for the three and nine months ended September 30, 2022 was $8.7 million and $29.9 million, respectively. Depreciation expense, net of amounts capitalized into inventory, for the three and nine months ended September 30, 2021 was $11.4 million and $35.7 million, respectively. Intangible Assets, Net consisted of the following: September 30, December 31, Finite-lived intangible assets $ 690,334 $ 677,350 Accumulated amortization (336,310) (288,698) Net carrying value $ 354,024 $ 388,652 Accounts Payable and Accrued Liabilities consisted of the following: September 30, December 31, Accounts payable and accrued operating expenses $ 207,165 $ 199,678 Accrued compensation expense 161,112 204,446 Accrued rebates payable 71,653 47,987 Accrued royalties payable 14,487 15,215 Foreign currency exchange forward contracts 13,075 6,263 Lease liabilities 9,226 10,464 Accrued income taxes 7,573 1,213 Deferred revenue 415 6,956 Other 8,011 6,043 Total accounts payable and accrued liabilities $ 492,717 $ 498,265 Supplemental Statement of Comprehensive Income (Loss) Information Gain on Sale of Nonfinancial Assets, Net for the nine months ended September 30, 2022 consisted of the completed sale of a Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the Food and Drug Administration (FDA) in connection with the U.S. approval of VOXZOGO. As a result of the PRV sale, the Company recognized a $108.0 million net gain on sale of nonfinancial assets in the first quarter of 2022 in the Company's Consolidated Statement of Comprehensive Income.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The Company measures certain financial assets and liabilities at fair value in accordance with the policy described in Note 1 – Business Overview and Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2022 and December 31, 2021. Other than the Company’s fixed-rate convertible debt disclosed in Note 6 – Debt , there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2022 or December 31, 2021. Fair Value Measurements as of September 30, 2022 Significant Other Significant Total Assets: Other current assets: NQDC Plan assets $ 2,306 $ — $ 2,306 Other assets: NQDC Plan assets 18,889 — 18,889 Restricted investments (1) 2,439 — 2,439 Total other assets 21,328 — 21,328 Total assets $ 23,634 $ — $ 23,634 Liabilities: Current liabilities: NQDC Plan liability $ 2,306 $ — $ 2,306 Contingent consideration — 28,303 28,303 Total current liabilities 2,306 28,303 30,609 Other long-term liabilities: NQDC Plan liability 18,889 — 18,889 Total liabilities $ 21,195 $ 28,303 $ 49,498 Fair Value Measurements as of December 31, 2021 Significant Other Significant Total Assets: Other current assets: NQDC Plan assets $ 2,043 $ — $ 2,043 Other assets: NQDC Plan assets 23,929 — 23,929 Restricted investments (1) 2,940 — 2,940 Total other assets 26,869 — 26,869 Total assets $ 28,912 $ — $ 28,912 Liabilities: Current liabilities: NQDC Plan liability $ 2,043 $ — $ 2,043 Contingent consideration — 48,232 48,232 Total current liabilities 2,043 48,232 50,275 Other long-term liabilities: NQDC Plan liability 23,929 — 23,929 Contingent consideration — 15,167 15,167 Total other long-term liabilities 23,929 15,167 39,096 Total liabilities $ 25,972 $ 63,399 $ 89,371 (1) The restricted investments at September 30, 2022 and December 31, 2021 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements. There were no transfers between levels during the three and nine months ended September 30, 2022. Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following table represents a roll-forward of contingent consideration. Contingent consideration as of December 31, 2021 $ 63,399 Milestone payments to Ares Trading S.A. (Merck Serono) (33,293) Realized foreign exchange gain on settlement of contingent consideration (133) Changes in fair value of contingent consideration 3,764 Foreign exchange remeasurement of Euro denominated contingent consideration (5,434) Contingent consideration as of September 30, 2022 $ 28,303

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES	DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES The Company uses foreign currency exchange forward contracts (forward contracts) to protect against the impact of changes in the value of forecasted foreign currency cash flows resulting from revenues and operating expenses denominated in currencies other than the U.S. Dollar (USD), primarily the Euro. Certain of these forward contracts are designated as cash flow hedges and have maturities of up to two years. The Company also enters into forward contracts to manage foreign exchange risk related to asset or liability positions denominated in currencies other than USD. Such forward contracts are considered to be economic hedges, are not designated as hedging instruments and have maturities of up to three months. The Company does not use derivative instruments for speculative trading purposes. The Company is exposed to counterparty credit risk on its derivatives. The Company has established and maintains strict counterparty credit guidelines and enters into hedging agreements with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company is not required to pledge collateral under these agreements. The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented. Forward Contracts September 30, 2022 December 31, 2021 Derivatives designated as hedging instruments: Sell $ 483,387 $ 740,667 Purchase $ 99,212 $ 183,256 Derivatives not designated as hedging instruments: Sell $ 118,026 $ 113,257 Purchase $ 5,812 $ 31,068 The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows: Balance Sheet Location September 30, 2022 December 31, 2021 Derivatives designated as hedging instruments: Asset Derivatives - Level 2 (1) Other current assets $ 51,050 $ 17,357 Other assets 10,012 4,991 Subtotal $ 61,062 $ 22,348 Liability Derivatives - Level 2 (1) Accounts payable and accrued liabilities $ 12,979 $ 5,487 Other long-term liabilities 2,226 1,378 Subtotal $ 15,205 $ 6,865 Derivatives not designated as hedging instruments: Asset Derivatives - Level 2 (1) Other current assets $ 81 $ 427 Liability Derivatives - Level 2 (1) Accounts payable and accrued liabilities $ 96 $ 776 Total Derivatives Assets $ 61,143 $ 22,775 Total Derivatives Liabilities $ 15,301 $ 7,641 (1) For additional discussion of fair value measurements, see Note 1 – Business Overview and Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented. Three Months Ended September 30, 2022 2021 Derivatives Designated as Cash Flow Hedging Instruments Cash Flow Hedging Gains (Losses) Cash Flow Hedging Gains (Losses) Net product revenues as reported $ 493,348 $ 15,280 $ 393,840 $ 401 Operating expenses as reported $ 507,761 $ (3,936) $ 461,961 $ (268) Derivatives Not Designated as Hedging Instruments Gains (Losses) Recognized in Earnings Gains (Losses) Recognized in Earnings Operating expenses $ 6,572 $ 1,302 Nine Months Ended September 30, 2022 2021 Derivatives Designated as Cash Flow Hedging Instruments Cash Flow Hedging Gains (Losses) Cash Flow Hedging Gains (Losses) Net product revenues as reported $ 1,516,533 $ 26,779 $ 1,348,279 $ (5,034) Operating expenses as reported $ 1,384,439 $ (7,115) $ 1,412,926 $ 81 Derivatives Not Designated as Hedging Instruments Gains (Losses) Recognized in Earnings Gains (Losses) Recognized in Earnings Operating expenses $ 12,812 $ 2,310 As of September 30, 2022, the Company expects to reclassify unrealized gains of $38.2 million from Accumulated Other Comprehensive Income (AOCI) to earnings as the forecasted revenues and operating expense transactions occur over the next twelve months. For additional discussion of balances in AOCI see Note 7 – Accumulated Other Comprehensive Income .

DEBT

DEBT	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
DEBT	DEBT Convertible Notes As of September 30, 2022, the Company had outstanding fixed-rate notes with varying maturities for an undiscounted aggregate principal amount of $1.1 billion (collectively the Notes). The Notes are senior subordinated convertible obligations, and interest is payable in arrears, semi-annually. The following table summarizes information regarding the Company’s convertible debt: September 30, December 31, 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes) $ 600,000 $ 600,000 Unamortized discount net of deferred offering costs (9,449) (10,971) 2027 Notes, net 590,551 589,029 0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) 495,000 495,000 Unamortized discount net of deferred offering costs (3,518) (4,952) 2024 Notes, net 491,482 490,048 Total convertible debt, net $ 1,082,033 $ 1,079,077 Fair value of fixed-rate convertible debt (1) : 2027 Notes $ 601,488 $ 625,122 2024 Notes 491,213 521,082 Total fair value of fixed-rate convertible debt $ 1,092,701 $ 1,146,204 (1) The fair value of the Company’s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 – Business Overview and Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Interest expense on the Company’s convertible debt consisted of the following: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Coupon interest expense $ 2,616 $ 2,617 $ 7,849 $ 7,849 Accretion of discount on convertible notes 838 835 2,511 2,503 Amortization of debt issuance costs 148 148 445 445 Total interest expense on convertible debt $ 3,602 $ 3,600 $ 10,805 $ 10,797 See Note 10 - Debt included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 for additional information related to the Company’s convertible debt. Revolving Credit Facility In October 2018, the Company entered into an unsecured revolving credit facility of up to $200.0 million which includes a letter of credit subfacility and a swingline loan subfacility. The credit facility is intended to finance ongoing working capital needs and for other general corporate purposes. In May 2021, the Company entered into an amendment agreement in respect of the credit facility, extending the maturity date from October 19, 2021 to May 28, 2024, among other changes. The amended credit facility contains financial covenants including a maximum leverage ratio and a minimum interest coverage ratio. As of September 30, 2022, there were no amounts outstanding under the credit facility and the Company and certain of its subsidiaries that serve as guarantors were in compliance with all covenants.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income and reclassifications out of AOCI, for the periods presented. Three Months Ended September 30, 2022 Unrealized Gains Unrealized Gains Total AOCI balance at June 30, 2022 $ 30,515 $ (12,043) $ 18,472 Other comprehensive income (loss) before 26,698 (4,011) 22,687 Less: gain (loss) reclassified from AOCI 11,344 — 11,344 Tax effect — 934 934 Net current-period other comprehensive income (loss) 15,354 (3,077) 12,277 AOCI balance at September 30, 2022 $ 45,869 $ (15,120) $ 30,749 Three Months Ended September 30, 2021 Unrealized Gains Unrealized Gains Total AOCI balance at June 30, 2021 $ (2,760) $ 1,821 $ (939) Other comprehensive income (loss) before 11,914 (786) 11,128 Less: gain (loss) reclassified from AOCI 133 — 133 Tax effect — 183 183 Net current-period other comprehensive income (loss) 11,781 (603) 11,178 AOCI balance at September 30, 2021 $ 9,021 $ 1,218 $ 10,239 Nine Months Ended September 30, 2022 Unrealized Gains Unrealized Gains Total AOCI balance at December 31, 2021 $ 15,805 $ (1,373) $ 14,432 Other comprehensive income (loss) before 49,728 (17,905) 31,823 Less: gain (loss) reclassified from AOCI 19,664 — 19,664 Tax effect — 4,158 4,158 Net current-period other comprehensive income (loss) 30,064 (13,747) 16,317 AOCI balance at September 30, 2022 $ 45,869 $ (15,120) $ 30,749 Nine Months Ended September 30, 2021 Unrealized Gains Unrealized Gains Total AOCI balance at December 31, 2020 $ (20,028) $ 3,889 $ (16,139) Other comprehensive income (loss) before 24,096 (3,470) 20,626 Less: gain (loss) reclassified from AOCI (4,953) — (4,953) Tax effect — 799 799 Net current-period other comprehensive income (loss) 29,049 (2,671) 26,378 AOCI balance at September 30, 2021 $ 9,021 $ 1,218 $ 10,239 For additional discussion of reclassifications from AOCI see Note 5 – Derivative Instruments and Hedging Strategies .

REVENUE, CREDIT CONCENTRATIONS

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION	9 Months Ended
	Sep. 30, 2022
Concentration Risk And Geographic Information [Abstract]
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION	REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The following table disaggregates total Net Product Revenues by product. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net product revenues by product: VIMIZIM $ 155,470 $ 136,744 $ 511,735 $ 466,697 NAGLAZYME 99,506 71,172 343,320 297,321 PALYNZIQ 66,206 60,729 182,734 173,702 KUVAN 57,038 67,687 173,977 217,257 VOXZOGO 48,289 144 102,321 144 BRINEURA 37,793 32,984 111,691 90,641 Total net product revenues marketed by the Company 464,302 369,460 1,425,778 1,245,762 ALDURAZYME net product revenues marketed by Sanofi 29,046 24,380 90,755 102,517 Total net product revenues 493,348 393,840 1,516,533 1,348,279 Royalty and other revenues 11,996 14,902 41,968 48,186 Total revenues $ 505,344 $ 408,742 $ 1,558,501 $ 1,396,465 The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is sold exclusively by Sanofi worldwide. Three Months Ended Nine Months Ended 2022 2021 2022 2021 United States $ 176,552 $ 166,554 $ 497,205 $ 491,028 Europe 162,583 108,568 480,645 424,144 Latin America 60,791 38,958 213,246 140,911 Rest of world 64,376 55,380 234,682 189,679 Total net product revenues marketed by the Company $ 464,302 $ 369,460 $ 1,425,778 $ 1,245,762 ALDURAZYME net product revenues marketed by Sanofi 29,046 24,380 90,755 102,517 Total net product revenues $ 493,348 $ 393,840 $ 1,516,533 $ 1,348,279 The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Customer A 15 % 20 % 16 % 17 % Customer B 14 % 16 % 12 % 14 % Customer C 10 % 11 % 9 % 10 % Total 39 % 47 % 37 % 41 % On a consolidated basis, two customers accounted for 23% and 15% of the Company’s September 30, 2022 accounts receivable balance, respectively, compared to December 31, 2021, when two customers accounted for 28% and 16% of the accounts receivable balance, respectively. As of September 30, 2022, and December 31, 2021, the accounts receivable balance for Sanofi included $65.3 million and $67.9 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances. The Company's global revenue sources and its business operations were impacted by the COVID-19 pandemic during the nine months ended September 30, 2022 and 2021, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and the Company anticipates a continued impact due to COVID-19 on its financial results in 2022. The extent and duration of such effects remain uncertain and difficult to predict, particularly as virus variants continue to spread. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations. The Company is mindful that conditions in the current macroeconomic environment, such as inflation, supply chain disruptions and impacts of the ongoing COVID-19 pandemic, could affect the Company’s ability to achieve its goals. In addition, the Company sells its products in certain countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The Company has stockholder-approved equity incentive plans that provide for the granting of service-based restricted stock units (RSUs), market-based RSUs, performance-based RSUs, stock options and common stock granted under the Company’s Employee Share Purchase Plan (ESPP) to its employees, officers and non-employee directors. Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of sales $ 4,361 $ 4,339 $ 13,449 $ 16,907 Research and development 17,055 17,866 47,878 56,199 Selling, general and administrative (SG&A) 33,247 26,821 88,247 80,266 Total stock-based compensation expense $ 54,663 $ 49,026 $ 149,574 $ 153,372

NET INCOME PER COMMON SHARE

NET INCOME PER COMMON SHARE	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
NET INCOME PER COMMON SHARE	NET INCOME PER COMMON SHARE Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the ESPP, unvested RSUs and contingent issuances of common stock related to the Company’s convertible debt. The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator: Net Income (loss), basic $ (6,652) $ (36,494) $ 141,810 $ (6,182) Add: Interest expense, net of tax, on the 2024 Notes — — 2,806 — Net Income (loss), diluted $ (6,652) $ (36,494) $ 144,616 $ (6,182) Denominator: Weighted-average common shares outstanding, basic 185,597 183,214 185,009 182,616 Effect of dilutive securities: Issuances under equity incentive plans — — 3,273 — Common stock issuable under the 2024 Notes — — 3,970 — Weighted-average common shares outstanding, diluted 185,597 183,214 192,252 182,616 Net income (loss) per common share, basic $ (0.04) $ (0.20) $ 0.77 $ (0.03) Net income (loss) per common share, diluted $ (0.04) $ (0.20) $ 0.75 $ (0.03) In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income per common share as they were anti-dilutive (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Issuances under equity incentive plans 12,221 12,720 8,948 12,720 Common stock issuable under the Company's convertible notes 8,335 8,335 4,365 8,335 Total number of potentially issuable shares 20,556 21,055 13,313 21,055

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Contingencies From time to time the Company is involved in legal actions arising in the normal course of its business. The process of resolving matters through litigation or other means is inherently uncertain and it is possible that an unfavorable resolution of these matters could adversely affect the Company, its results of operations, financial condition or cash flows. The Company’s general practice is to expense legal fees as services are rendered in connection with legal matters, and to accrue for liabilities when losses are probable and reasonably estimable. Contingent Payments As of September 30, 2022, the Company was subject to contingent payments considered reasonably possible of $777.6 million, including $381.5 million related to an early-stage development program licensed from a third party in the fourth quarter of 2021 and $225.0 million related to an early-stage development program licensed from a third party in the second quarter of 2020. Other Commitments The Company uses experts and laboratories at universities and other institutions to perform certain Research and Development (R&D) activities. These amounts are included as R&D expense as services are provided. In the normal course of business, the Company enters into various firm purchase commitments primarily to procure active pharmaceutical ingredients, certain inventory-related items and certain third-party R&D services, production services and facility construction services. As of September 30, 2022, such commitments were estimated at approximately $171.5 million. The Company has also licensed technology from third parties, for which it is required to pay royalties upon future sales, subject to certain annual minimums.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENTOn October 6, 2022, the Company announced a plan to simplify its organizational design, which included a reduction in force of approximately 120 employees (representing approximately 4% of the Company’s global workforce). The reduction in force primarily impacts U.S. employees and is expected to be substantially completed by December 31, 2022. As a result of the reduction in force, the Company expects to incur total estimated pre-tax charges of approximately $20.0 million to $25.0 million representing cash expenditures for severance and employee termination benefits. The Company accrued $4.8 million in SG&A in the third quarter of 2022 and the remainder of the estimated charges are expected to be recorded in the fourth quarter of 2022.

BUSINESS OVERVIEW AND SIGNIFI_2

BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the Securities and Exchange Commission (the SEC) for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K. The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022 or any other period.
Use of Estimates	Use of Estimates U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the COVID-19 pandemic could continue to directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that remain uncertain at this time, particularly as virus variants continue to spread. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods. Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements except for the transaction disclosed in Note 12 to these Condensed Consolidated Financial Statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the nine months ended September 30, 2022, as compared to the recent accounting pronouncements described in Note 1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, that the Company believes are of significance or potential significance to the Company.

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	9 Months Ended
	Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category	The following tables show the Company’s cash, cash equivalents and available-for-sale securities by significant investment category for each period presented: September 30, 2022 Amortized Cost Gross Gross Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash $ 358,325 $ — $ — $ 358,325 $ 358,325 $ — $ — Level 2: Money market instruments 347,274 — — 347,274 347,274 — — Corporate debt securities 522,723 10 (14,622) 508,111 978 273,333 233,800 U.S. government agency securities 354,810 4 (4,377) 350,437 54,938 209,469 86,030 Commercial paper 29,461 1 (22) 29,440 — 29,440 — Asset-backed securities 53,182 — (699) 52,483 — 11 52,472 Subtotal 1,307,450 15 (19,720) 1,287,745 403,190 512,253 372,302 Total $ 1,665,775 $ 15 $ (19,720) $ 1,646,070 $ 761,515 $ 512,253 $ 372,302 December 31, 2021 Amortized Cost Gross Gross Aggregate Fair Value Cash and Cash Equivalents Short-term Marketable Securities (1) Long-term Marketable Securities (2) Level 1: Cash $ 301,177 $ — $ — $ 301,177 $ 301,177 $ — $ — Level 2: Money market instruments 285,099 — — 285,099 285,099 — — Corporate debt securities 584,000 386 (2,086) 582,300 — 200,304 381,996 U.S. government agency securities 224,774 182 (325) 224,631 — 146,421 78,210 Commercial paper 68,384 — — 68,384 1,000 67,384 — Asset-backed securities 56,936 10 (95) 56,851 — 9,451 47,400 Foreign and other 3,097 141 (12) 3,226 — 3,039 187 Subtotal 1,222,290 719 (2,518) 1,220,491 286,099 426,599 507,793 Total $ 1,523,467 $ 719 $ (2,518) $ 1,521,668 $ 587,276 $ 426,599 $ 507,793 (1) The Company’s short-term marketable securities mature in one year or less. (2) The Company’s long-term marketable securities mature between one

SUPPLEMENTAL FINANCIAL STATEM_2

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	Inventory consisted of the following: September 30, December 31, Raw materials $ 109,480 $ 80,269 Work-in-process 425,505 415,261 Finished goods 304,475 281,139 Total inventory $ 839,460 $ 776,669
Schedule of Property Plant and Equipment Net	Property, Plant and Equipment, Net consisted of the following: September 30, December 31, Property, plant and equipment, gross $ 1,834,220 $ 1,756,035 Accumulated depreciation (782,399) (720,574) Total property, plant and equipment, net $ 1,051,821 $ 1,035,461
Schedule of Intangible Assets	Intangible Assets, Net consisted of the following: September 30, December 31, Finite-lived intangible assets $ 690,334 $ 677,350 Accumulated amortization (336,310) (288,698) Net carrying value $ 354,024 $ 388,652
Schedule of Accounts Payable and Accrued Liabilities	Accounts Payable and Accrued Liabilities consisted of the following: September 30, December 31, Accounts payable and accrued operating expenses $ 207,165 $ 199,678 Accrued compensation expense 161,112 204,446 Accrued rebates payable 71,653 47,987 Accrued royalties payable 14,487 15,215 Foreign currency exchange forward contracts 13,075 6,263 Lease liabilities 9,226 10,464 Accrued income taxes 7,573 1,213 Deferred revenue 415 6,956 Other 8,011 6,043 Total accounts payable and accrued liabilities $ 492,717 $ 498,265

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	The following tables present the classification within the fair value hierarchy of financial assets and liabilities not disclosed elsewhere in these Condensed Consolidated Financial Statements that are remeasured on a recurring basis as of September 30, 2022 and December 31, 2021. Other than the Company’s fixed-rate convertible debt disclosed in Note 6 – Debt , there were no financial assets or liabilities that were remeasured using a quoted price in active markets for identical assets (Level 1) as of September 30, 2022 or December 31, 2021. Fair Value Measurements as of September 30, 2022 Significant Other Significant Total Assets: Other current assets: NQDC Plan assets $ 2,306 $ — $ 2,306 Other assets: NQDC Plan assets 18,889 — 18,889 Restricted investments (1) 2,439 — 2,439 Total other assets 21,328 — 21,328 Total assets $ 23,634 $ — $ 23,634 Liabilities: Current liabilities: NQDC Plan liability $ 2,306 $ — $ 2,306 Contingent consideration — 28,303 28,303 Total current liabilities 2,306 28,303 30,609 Other long-term liabilities: NQDC Plan liability 18,889 — 18,889 Total liabilities $ 21,195 $ 28,303 $ 49,498 Fair Value Measurements as of December 31, 2021 Significant Other Significant Total Assets: Other current assets: NQDC Plan assets $ 2,043 $ — $ 2,043 Other assets: NQDC Plan assets 23,929 — 23,929 Restricted investments (1) 2,940 — 2,940 Total other assets 26,869 — 26,869 Total assets $ 28,912 $ — $ 28,912 Liabilities: Current liabilities: NQDC Plan liability $ 2,043 $ — $ 2,043 Contingent consideration — 48,232 48,232 Total current liabilities 2,043 48,232 50,275 Other long-term liabilities: NQDC Plan liability 23,929 — 23,929 Contingent consideration — 15,167 15,167 Total other long-term liabilities 23,929 15,167 39,096 Total liabilities $ 25,972 $ 63,399 $ 89,371 (1) The restricted investments at September 30, 2022 and December 31, 2021 secure the Company's irrevocable standby letters of credit obtained in connection with certain commercial agreements.
Schedule of Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs	Liabilities measured at fair value using Level 3 inputs consisted of contingent consideration. The following table represents a roll-forward of contingent consideration. Contingent consideration as of December 31, 2021 $ 63,399 Milestone payments to Ares Trading S.A. (Merck Serono) (33,293) Realized foreign exchange gain on settlement of contingent consideration (133) Changes in fair value of contingent consideration 3,764 Foreign exchange remeasurement of Euro denominated contingent consideration (5,434) Contingent consideration as of September 30, 2022 $ 28,303

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES (Tables)	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivatives Designated as Hedging Instruments Outstanding	The following table summarizes the aggregate notional amounts for the Company’s derivatives outstanding as of the periods presented. Forward Contracts September 30, 2022 December 31, 2021 Derivatives designated as hedging instruments: Sell $ 483,387 $ 740,667 Purchase $ 99,212 $ 183,256 Derivatives not designated as hedging instruments: Sell $ 118,026 $ 113,257 Purchase $ 5,812 $ 31,068
Schedule of Fair Value Carrying Amount of Derivatives	The fair value carrying amounts of the Company’s derivatives, as classified within the fair value hierarchy, were as follows: Balance Sheet Location September 30, 2022 December 31, 2021 Derivatives designated as hedging instruments: Asset Derivatives - Level 2 (1) Other current assets $ 51,050 $ 17,357 Other assets 10,012 4,991 Subtotal $ 61,062 $ 22,348 Liability Derivatives - Level 2 (1) Accounts payable and accrued liabilities $ 12,979 $ 5,487 Other long-term liabilities 2,226 1,378 Subtotal $ 15,205 $ 6,865 Derivatives not designated as hedging instruments: Asset Derivatives - Level 2 (1) Other current assets $ 81 $ 427 Liability Derivatives - Level 2 (1) Accounts payable and accrued liabilities $ 96 $ 776 Total Derivatives Assets $ 61,143 $ 22,775 Total Derivatives Liabilities $ 15,301 $ 7,641 (1) For additional discussion of fair value measurements, see Note 1 – Business Overview and Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Schedule of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments	The following tables summarize the impact of gains and losses from the Company's derivatives on its Condensed Consolidated Statements of Comprehensive Income for the periods presented. Three Months Ended September 30, 2022 2021 Derivatives Designated as Cash Flow Hedging Instruments Cash Flow Hedging Gains (Losses) Cash Flow Hedging Gains (Losses) Net product revenues as reported $ 493,348 $ 15,280 $ 393,840 $ 401 Operating expenses as reported $ 507,761 $ (3,936) $ 461,961 $ (268) Derivatives Not Designated as Hedging Instruments Gains (Losses) Recognized in Earnings Gains (Losses) Recognized in Earnings Operating expenses $ 6,572 $ 1,302 Nine Months Ended September 30, 2022 2021 Derivatives Designated as Cash Flow Hedging Instruments Cash Flow Hedging Gains (Losses) Cash Flow Hedging Gains (Losses) Net product revenues as reported $ 1,516,533 $ 26,779 $ 1,348,279 $ (5,034) Operating expenses as reported $ 1,384,439 $ (7,115) $ 1,412,926 $ 81 Derivatives Not Designated as Hedging Instruments Gains (Losses) Recognized in Earnings Gains (Losses) Recognized in Earnings Operating expenses $ 12,812 $ 2,310

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Summary of Convertible Debt	The following table summarizes information regarding the Company’s convertible debt: September 30, December 31, 1.25% senior subordinated convertible notes due in May 2027 (the 2027 Notes) $ 600,000 $ 600,000 Unamortized discount net of deferred offering costs (9,449) (10,971) 2027 Notes, net 590,551 589,029 0.599% senior subordinated convertible notes due in August 2024 (the 2024 Notes) 495,000 495,000 Unamortized discount net of deferred offering costs (3,518) (4,952) 2024 Notes, net 491,482 490,048 Total convertible debt, net $ 1,082,033 $ 1,079,077 Fair value of fixed-rate convertible debt (1) : 2027 Notes $ 601,488 $ 625,122 2024 Notes 491,213 521,082 Total fair value of fixed-rate convertible debt $ 1,092,701 $ 1,146,204 (1) The fair value of the Company’s fixed-rate convertible debt is based on open-market trades and is classified as Level 1 in the fair value hierarchy. For additional discussion of fair value measurements, see Note 1 – Business Overview and Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
Summary of Interest Expense on Debt	Interest expense on the Company’s convertible debt consisted of the following: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Coupon interest expense $ 2,616 $ 2,617 $ 7,849 $ 7,849 Accretion of discount on convertible notes 838 835 2,511 2,503 Amortization of debt issuance costs 148 148 445 445 Total interest expense on convertible debt $ 3,602 $ 3,600 $ 10,805 $ 10,797

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI	The following tables summarize changes in the accumulated balances for each component of AOCI, including current-period other comprehensive income and reclassifications out of AOCI, for the periods presented. Three Months Ended September 30, 2022 Unrealized Gains Unrealized Gains Total AOCI balance at June 30, 2022 $ 30,515 $ (12,043) $ 18,472 Other comprehensive income (loss) before 26,698 (4,011) 22,687 Less: gain (loss) reclassified from AOCI 11,344 — 11,344 Tax effect — 934 934 Net current-period other comprehensive income (loss) 15,354 (3,077) 12,277 AOCI balance at September 30, 2022 $ 45,869 $ (15,120) $ 30,749 Three Months Ended September 30, 2021 Unrealized Gains Unrealized Gains Total AOCI balance at June 30, 2021 $ (2,760) $ 1,821 $ (939) Other comprehensive income (loss) before 11,914 (786) 11,128 Less: gain (loss) reclassified from AOCI 133 — 133 Tax effect — 183 183 Net current-period other comprehensive income (loss) 11,781 (603) 11,178 AOCI balance at September 30, 2021 $ 9,021 $ 1,218 $ 10,239 Nine Months Ended September 30, 2022 Unrealized Gains Unrealized Gains Total AOCI balance at December 31, 2021 $ 15,805 $ (1,373) $ 14,432 Other comprehensive income (loss) before 49,728 (17,905) 31,823 Less: gain (loss) reclassified from AOCI 19,664 — 19,664 Tax effect — 4,158 4,158 Net current-period other comprehensive income (loss) 30,064 (13,747) 16,317 AOCI balance at September 30, 2022 $ 45,869 $ (15,120) $ 30,749 Nine Months Ended September 30, 2021 Unrealized Gains Unrealized Gains Total AOCI balance at December 31, 2020 $ (20,028) $ 3,889 $ (16,139) Other comprehensive income (loss) before 24,096 (3,470) 20,626 Less: gain (loss) reclassified from AOCI (4,953) — (4,953) Tax effect — 799 799 Net current-period other comprehensive income (loss) 29,049 (2,671) 26,378 AOCI balance at September 30, 2021 $ 9,021 $ 1,218 $ 10,239

REVENUE, CREDIT CONCENTRATION_2

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2022
Concentration Risk And Geographic Information [Abstract]
Schedule of Net Product Revenues by Product	The following table disaggregates total Net Product Revenues by product. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net product revenues by product: VIMIZIM $ 155,470 $ 136,744 $ 511,735 $ 466,697 NAGLAZYME 99,506 71,172 343,320 297,321 PALYNZIQ 66,206 60,729 182,734 173,702 KUVAN 57,038 67,687 173,977 217,257 VOXZOGO 48,289 144 102,321 144 BRINEURA 37,793 32,984 111,691 90,641 Total net product revenues marketed by the Company 464,302 369,460 1,425,778 1,245,762 ALDURAZYME net product revenues marketed by Sanofi 29,046 24,380 90,755 102,517 Total net product revenues 493,348 393,840 1,516,533 1,348,279 Royalty and other revenues 11,996 14,902 41,968 48,186 Total revenues $ 505,344 $ 408,742 $ 1,558,501 $ 1,396,465
Schedule of Total Net Product Revenues Based on Patient Location	The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for ALDURAZYME, which is sold exclusively by Sanofi worldwide. Three Months Ended Nine Months Ended 2022 2021 2022 2021 United States $ 176,552 $ 166,554 $ 497,205 $ 491,028 Europe 162,583 108,568 480,645 424,144 Latin America 60,791 38,958 213,246 140,911 Rest of world 64,376 55,380 234,682 189,679 Total net product revenues marketed by the Company $ 464,302 $ 369,460 $ 1,425,778 $ 1,245,762 ALDURAZYME net product revenues marketed by Sanofi 29,046 24,380 90,755 102,517 Total net product revenues $ 493,348 $ 393,840 $ 1,516,533 $ 1,348,279
Schedule of Net Product Revenue Concentrations Attributed to Largest Customers	The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Customer A 15 % 20 % 16 % 17 % Customer B 14 % 16 % 12 % 14 % Customer C 10 % 11 % 9 % 10 % Total 39 % 47 % 37 % 41 %

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	Compensation expense included in the Company’s Condensed Consolidated Statements of Comprehensive Income for all stock-based compensation arrangements was as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Cost of sales $ 4,361 $ 4,339 $ 13,449 $ 16,907 Research and development 17,055 17,866 47,878 56,199 Selling, general and administrative (SG&A) 33,247 26,821 88,247 80,266 Total stock-based compensation expense $ 54,663 $ 49,026 $ 149,574 $ 153,372

NET INCOME PER COMMON SHARE (Ta

NET INCOME PER COMMON SHARE (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per common share (common shares in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Numerator: Net Income (loss), basic $ (6,652) $ (36,494) $ 141,810 $ (6,182) Add: Interest expense, net of tax, on the 2024 Notes — — 2,806 — Net Income (loss), diluted $ (6,652) $ (36,494) $ 144,616 $ (6,182) Denominator: Weighted-average common shares outstanding, basic 185,597 183,214 185,009 182,616 Effect of dilutive securities: Issuances under equity incentive plans — — 3,273 — Common stock issuable under the 2024 Notes — — 3,970 — Weighted-average common shares outstanding, diluted 185,597 183,214 192,252 182,616 Net income (loss) per common share, basic $ (0.04) $ (0.20) $ 0.77 $ (0.03) Net income (loss) per common share, diluted $ (0.04) $ (0.20) $ 0.75 $ (0.03)
Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share	In addition to the equity instruments included in the table above, the table below presents potential shares of common stock that were excluded from the computation of basic and diluted income per common share as they were anti-dilutive (in thousands): Three Months Ended Nine Months Ended 2022 2021 2022 2021 Issuances under equity incentive plans 12,221 12,720 8,948 12,720 Common stock issuable under the Company's convertible notes 8,335 8,335 4,365 8,335 Total number of potentially issuable shares 20,556 21,055 13,313 21,055

BUSINESS OVERVIEW AND SIGNIFI_3

BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) commercial_product	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)		Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2020 USD ($)
Change in Accounting Estimate [Line Items]
Number of commercial products in portfolio | commercial_product	8
Accumulated deficit	$ 788,949		$ 930,759	[1]
Decrease in stockholders’ equity	(4,568,514)	$ (4,499,737)	(4,265,670)	[1]	$ (4,261,078)	$ (4,236,500)	$ (4,100,931)
Deferred tax assets	1,455,205		1,450,161	[1]
Other assets	151,788		152,121	[1]
Other long-term liabilities	$ (92,473)		(98,361)	[1]
Revision of Prior Period, Error Correction, Adjustment
Change in Accounting Estimate [Line Items]
Accumulated deficit							5,100
Decrease in stockholders’ equity		$ 5,071	5,071			$ 5,071	$ 5,071
Accounts payable and accrued liabilities			6,700
Deferred tax assets			1,100
Other assets			400
Other long-term liabilities			$ 100
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

FINANCIAL INSTRUMENTS - Schedul

FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Available-for-Sale Securities by Significant Investment Category (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 1,665,775	$ 1,523,467
Gross Unrealized Gains	15	719
Gross Unrealized Losses	(19,720)	(2,518)
Aggregate Fair Value	1,646,070	1,521,668
Cash and Cash Equivalents	761,515	587,276	[1]
Short-term Marketable Securities	512,253	426,599	[1]
Long-term Marketable Securities	372,302	507,793	[1]
Level 1: | Cash
Schedule of Available-for-sale Securities [Line Items]
Cash	358,325	301,177
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	358,325	301,177
Cash and Cash Equivalents	358,325	301,177
Short-term Marketable Securities	0	0
Long-term Marketable Securities	0	0
Level 2:
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	1,307,450	1,222,290
Gross Unrealized Gains	15	719
Gross Unrealized Losses	(19,720)	(2,518)
Aggregate Fair Value	1,287,745	1,220,491
Cash and Cash Equivalents	403,190	286,099
Short-term Marketable Securities	512,253	426,599
Long-term Marketable Securities	372,302	507,793
Level 2: | Money market instruments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	347,274	285,099
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	347,274	285,099
Cash and Cash Equivalents	347,274	285,099
Short-term Marketable Securities	0	0
Long-term Marketable Securities	0	0
Level 2: | Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	522,723	584,000
Gross Unrealized Gains	10	386
Gross Unrealized Losses	(14,622)	(2,086)
Aggregate Fair Value	508,111	582,300
Cash and Cash Equivalents	978	0
Short-term Marketable Securities	273,333	200,304
Long-term Marketable Securities	233,800	381,996
Level 2: | U.S. government agency securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	354,810	224,774
Gross Unrealized Gains	4	182
Gross Unrealized Losses	(4,377)	(325)
Aggregate Fair Value	350,437	224,631
Cash and Cash Equivalents	54,938	0
Short-term Marketable Securities	209,469	146,421
Long-term Marketable Securities	86,030	78,210
Level 2: | Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	29,461	68,384
Gross Unrealized Gains	1	0
Gross Unrealized Losses	(22)	0
Aggregate Fair Value	29,440	68,384
Cash and Cash Equivalents	0	1,000
Short-term Marketable Securities	29,440	67,384
Long-term Marketable Securities	0	0
Level 2: | Asset-backed securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	53,182	56,936
Gross Unrealized Gains	0	10
Gross Unrealized Losses	(699)	(95)
Aggregate Fair Value	52,483	56,851
Cash and Cash Equivalents	0	0
Short-term Marketable Securities	11	9,451
Long-term Marketable Securities	$ 52,472	47,400
Level 2: | Foreign and other
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		3,097
Gross Unrealized Gains		141
Gross Unrealized Losses		(12)
Aggregate Fair Value		3,226
Cash and Cash Equivalents		0
Short-term Marketable Securities		3,039
Long-term Marketable Securities		$ 187
Minimum
Schedule of Available-for-sale Securities [Line Items]
Long term marketable securities maturity period	1 year	1 year
Maximum
Schedule of Available-for-sale Securities [Line Items]
Short term marketable securities maturity period	1 year	1 year
Long term marketable securities maturity period	5 years	5 years
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

FINANCIAL INSTRUMENTS - Additio

FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Strategic Investment | Fair Value, Measurements, Recurring
Schedule of Available-for-sale Securities [Line Items]
Strategic investments fair value	$ 23.7	$ 16.5

SUPPLEMENTAL FINANCIAL STATEM_3

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 109,480	$ 80,269
Work-in-process	425,505	415,261
Finished goods	304,475	281,139
Total inventory	$ 839,460	$ 776,669	[1]
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

SUPPLEMENTAL FINANCIAL STATEM_4

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation expense, net of amounts capitalized into inventory	$ 8,700		$ 11,400	$ 29,900	$ 35,700
Gain on sale of nonfinancial assets, net	$ 0	$ 108,000	$ 0	$ 108,000	$ 0

SUPPLEMENTAL FINANCIAL STATEM_5

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Property, plant and equipment, gross	$ 1,834,220	$ 1,756,035
Accumulated depreciation	(782,399)	(720,574)
Property, plant and equipment, net	$ 1,051,821	$ 1,035,461	[1]
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

SUPPLEMENTAL FINANCIAL STATEM_6

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finite-lived intangible assets	$ 690,334	$ 677,350
Accumulated amortization	(336,310)	(288,698)
Net carrying value	$ 354,024	$ 388,652	[1]
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

SUPPLEMENTAL FINANCIAL STATEM_7

SUPPLEMENTAL FINANCIAL STATEMENTS INFORMATION - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts payable and accrued operating expenses	$ 207,165	$ 199,678
Accrued compensation expense	161,112	204,446
Accrued rebates payable	71,653	47,987
Accrued royalties payable	14,487	15,215
Foreign currency exchange forward contracts	13,075	6,263
Lease liabilities	9,226	10,464
Accrued income taxes	7,573	1,213
Deferred revenue	415	6,956
Other	8,011	6,043
Accounts payable and accrued liabilities	$ 492,717	$ 498,265	[1]
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

FAIR VALUE MEASUREMENTS - Fair

FAIR VALUE MEASUREMENTS - Fair Value of Financial Assets and Liabilities (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Quoted Price in Active Markets For Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets remeasured	$ 0	$ 0
Liabilities remeasured	0	0
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other non-current assets	21,328,000	26,869,000
Fair value of financial assets, Total	23,634,000	28,912,000
Fair value of other current liabilities	30,609,000	50,275,000
Fair value of other non-current liabilities		39,096,000
Fair value of financial liabilities, Total	49,498,000	89,371,000
Fair Value, Measurements, Recurring | NQDC Plan liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current liabilities	2,306,000	2,043,000
Fair value of other non-current liabilities	18,889,000	23,929,000
Fair Value, Measurements, Recurring | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current liabilities	28,303,000	48,232,000
Fair value of other non-current liabilities		15,167,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other non-current assets	21,328,000	26,869,000
Fair value of financial assets, Total	23,634,000	28,912,000
Fair value of other current liabilities	2,306,000	2,043,000
Fair value of other non-current liabilities		23,929,000
Fair value of financial liabilities, Total	21,195,000	25,972,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | NQDC Plan liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current liabilities	2,306,000	2,043,000
Fair value of other non-current liabilities	18,889,000	23,929,000
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current liabilities	0	0
Fair value of other non-current liabilities		0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other non-current assets	0	0
Fair value of financial assets, Total	0	0
Fair value of other current liabilities	28,303,000	48,232,000
Fair value of other non-current liabilities		15,167,000
Fair value of financial liabilities, Total	28,303,000	63,399,000
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | NQDC Plan liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current liabilities	0	0
Fair value of other non-current liabilities	0	0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current liabilities	28,303,000	48,232,000
Fair value of other non-current liabilities		15,167,000
Fair Value, Measurements, Recurring | NQDC Plan assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current assets	2,306,000	2,043,000
Fair value of other non-current assets	18,889,000	23,929,000
Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current assets	2,306,000	2,043,000
Fair value of other non-current assets	18,889,000	23,929,000
Fair Value, Measurements, Recurring | NQDC Plan assets | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other current assets	0	0
Fair value of other non-current assets	0	0
Fair Value, Measurements, Recurring | Restricted Investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other non-current assets	2,439,000	2,940,000
Fair Value, Measurements, Recurring | Restricted Investments | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other non-current assets	2,439,000	2,940,000
Fair Value, Measurements, Recurring | Restricted Investments | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of other non-current assets	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Liabi

FAIR VALUE MEASUREMENTS - Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs (Details) - Contingent Payment $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration as of December 31, 2021	$ 63,399
Milestone payments to Ares Trading S.A. (Merck Serono)	(33,293)
Realized foreign exchange gain on settlement of contingent consideration	(133)
Changes in fair value of contingent consideration	3,764
Foreign exchange remeasurement of Euro denominated contingent consideration	(5,434)
Contingent consideration as of September 30, 2022	$ 28,303

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Additional Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Derivative [Line Items]
Amount reclassified from AOCI to earnings as related to forecasted revenue and operating expense transactions	$ 38.2
Derivatives Designated As Hedging Instruments
Derivative [Line Items]
Maturity of derivatives	2 years
Not Designated as Hedging Instrument
Derivative [Line Items]
Maturity of derivatives	3 months

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Derivatives Designated as and Not Designated as Hedging Instruments Outstanding (Details) - Forward Foreign Exchange Contracts - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Derivatives Designated As Hedging Instruments | Sell
Derivative [Line Items]
Notional amount	$ 483,387	$ 740,667
Derivatives Designated As Hedging Instruments | Purchase
Derivative [Line Items]
Notional amount	99,212	183,256
Not Designated as Hedging Instrument | Sell
Derivative [Line Items]
Notional amount	118,026	113,257
Not Designated as Hedging Instrument | Purchase
Derivative [Line Items]
Notional amount	$ 5,812	$ 31,068

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Fair Value Carrying Amount of Derivatives (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Derivative [Line Items]
Derivative asset, fair value	$ 61,143	$ 22,775
Derivative liability, fair value	15,301	7,641
Level 2: | Derivatives Designated As Hedging Instruments
Derivative [Line Items]
Derivative asset, fair value	61,062	22,348
Derivative liability, fair value	15,205	6,865
Level 2: | Derivatives Designated As Hedging Instruments | Other current assets
Derivative [Line Items]
Derivative asset, fair value	51,050	17,357
Level 2: | Derivatives Designated As Hedging Instruments | Other assets
Derivative [Line Items]
Derivative asset, fair value	10,012	4,991
Level 2: | Derivatives Designated As Hedging Instruments | Accounts payable and accrued liabilities
Derivative [Line Items]
Derivative liability, fair value	12,979	5,487
Level 2: | Derivatives Designated As Hedging Instruments | Other long-term liabilities
Derivative [Line Items]
Derivative liability, fair value	2,226	1,378
Level 2: | Not Designated as Hedging Instrument | Other current assets
Derivative [Line Items]
Derivative asset, fair value	81	427
Level 2: | Not Designated as Hedging Instrument | Accounts payable and accrued liabilities
Derivative [Line Items]
Derivative liability, fair value	$ 96	$ 776

DERIVATIVE INSTRUMENTS AND HE_6

DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES - Summary of Impact of Gains and Losses from Derivatives Designated as Hedging Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Revenue	$ 505,344	$ 408,742	$ 1,558,501	$ 1,396,465
Operating expenses	507,761	461,961	1,384,439	1,412,926
Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Gains (Losses) Recognized in Earnings	6,572	1,302	12,812	2,310
Operating expenses as reported | Derivatives Designated As Hedging Instruments | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Derivative Instruments, Gain (Loss) [Line Items]
Cash Flow Hedging Gains (Losses) Reclassified into Earnings	(3,936)	(268)	(7,115)	81
Net product revenues
Derivative Instruments, Gain (Loss) [Line Items]
Revenue	493,348	393,840	1,516,533	1,348,279
Net product revenues | Derivatives Designated As Hedging Instruments | Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
Derivative Instruments, Gain (Loss) [Line Items]
Cash Flow Hedging Gains (Losses) Reclassified into Earnings	$ 15,280	$ 401	$ 26,779	$ (5,034)

DEBT - Additional Information (

DEBT - Additional Information (Details) - USD ($)	Sep. 30, 2022	Oct. 31, 2018
Debt Instrument [Line Items]
Carrying value of equity component	$ 1,100,000,000
The 2018 Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 200,000,000
Outstanding amount	$ 0

DEBT - Summary of Convertible D

DEBT - Summary of Convertible Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Convertible notes	$ 1,100,000
Convertible notes, net of unamortized discount and deferred offering costs	1,082,033	$ 1,079,077	[1]
Total convertible debt, net	1,082,033	1,079,077
Total fair value of fixed-rate convertible debt	$ 1,092,701	$ 1,146,204
1.25% Senior Subordinated Convertible Notes Due in May 2027
Debt Instrument [Line Items]
Convertible notes stated rate	1.25%	1.25%
Convertible notes	$ 600,000	$ 600,000
Unamortized discount net of deferred offering costs	(9,449)	(10,971)
Convertible notes, net of unamortized discount and deferred offering costs	590,551	589,029
Total fair value of fixed-rate convertible debt	$ 601,488	$ 625,122
0.599% Senior Subordinated Convertible Notes Due in August 2024
Debt Instrument [Line Items]
Convertible notes stated rate	0.599%	0.599%
Convertible notes	$ 495,000	$ 495,000
Unamortized discount net of deferred offering costs	(3,518)	(4,952)
Convertible notes, net of unamortized discount and deferred offering costs	491,482	490,048
Total fair value of fixed-rate convertible debt	$ 491,213	$ 521,082
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

DEBT - Summary of Interest Expe

DEBT - Summary of Interest Expense on Convertible Debt (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Schedule Of Interest Expenses [Line Items]
Total interest expense on convertible debt	$ 4,679	$ 3,870	$ 12,344	$ 11,491
Convertible Senior Notes
Schedule Of Interest Expenses [Line Items]
Coupon interest expense	2,616	2,617	7,849	7,849
Accretion of discount on convertible notes	838	835	2,511	2,503
Amortization of debt issuance costs	148	148	445	445
Total interest expense on convertible debt	$ 3,602	$ 3,600	$ 10,805	$ 10,797

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME - Summary of Changes in Accumulated Balances of AOCI Including Current Period Other Comprehensive Income (Loss) and Reclassifications Out of AOCI (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022		Sep. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 4,499,737	$ 4,236,500	$ 4,265,670	[1]	$ 4,100,931
Other comprehensive income (loss) before      reclassifications	22,687	11,128	31,823		20,626
Less: gain (loss) reclassified from AOCI	11,344	133	19,664		(4,953)
Tax effect	934	183	4,158		799
Net current-period other comprehensive income (loss)	12,277	11,178	16,317		26,378
Ending balance	4,568,514	4,261,078	4,568,514		4,261,078
AOCI attributable to parent
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	18,472	(939)	14,432	[2]	(16,139)	[2]
Ending balance	30,749	10,239	30,749		10,239
Unrealized Gains (Losses) on Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	30,515	(2,760)	15,805		(20,028)
Other comprehensive income (loss) before      reclassifications	26,698	11,914	49,728		24,096
Less: gain (loss) reclassified from AOCI	11,344	133	19,664		(4,953)
Tax effect	0	0	0		0
Net current-period other comprehensive income (loss)	15,354	11,781	30,064		29,049
Ending balance	45,869	9,021	45,869		9,021
Unrealized Gains (Losses) on Available for-Sale Debt Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(12,043)	1,821	(1,373)		3,889
Other comprehensive income (loss) before      reclassifications	(4,011)	(786)	(17,905)		(3,470)
Less: gain (loss) reclassified from AOCI	0	0	0		0
Tax effect	934	183	4,158		799
Net current-period other comprehensive income (loss)	(3,077)	(603)	(13,747)		(2,671)
Ending balance	$ (15,120)	$ 1,218	$ (15,120)		$ 1,218
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

REVENUE, CREDIT CONCENTRATION_3

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Additional Information (Details) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)
Concentration Risk And Geographic Information [Line Items]
Number of operating business segment | Segment	1
Accounts receivable, net	$ 419,622	$ 373,399	[1]
Customers
Concentration Risk And Geographic Information [Line Items]
Accounts receivable, net	$ 65,300	$ 67,900
Credit Concentration Risk | Accounts Receivable | Customer One
Concentration Risk And Geographic Information [Line Items]
Concentration risk, percentage	23%	28%
Credit Concentration Risk | Accounts Receivable | Customer Two
Concentration Risk And Geographic Information [Line Items]
Concentration risk, percentage	15%	16%
[1] (1) Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.

REVENUE, CREDIT CONCENTRATION_4

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Net Product Revenues by Product (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue from External Customer [Line Items]
Revenue	$ 505,344	$ 408,742	$ 1,558,501	$ 1,396,465
Product
Revenue from External Customer [Line Items]
Revenue	493,348	393,840	1,516,533	1,348,279
VIMIZIM | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	155,470	136,744	511,735	466,697
NAGLAZYME | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	99,506	71,172	343,320	297,321
PALYNZIQ | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	66,206	60,729	182,734	173,702
KUVAN | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	57,038	67,687	173,977	217,257
VOXZOGO | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	48,289	144	102,321	144
BRINEURA | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	37,793	32,984	111,691	90,641
Total net product revenues marketed by the Company | Marketed by Company
Revenue from External Customer [Line Items]
Revenue	464,302	369,460	1,425,778	1,245,762
ALDURAZYME net product revenues marketed by Sanofi | Marketed by Sanofi
Revenue from External Customer [Line Items]
Revenue	29,046	24,380	90,755	102,517
Royalty and other revenues
Revenue from External Customer [Line Items]
Revenue	$ 11,996	$ 14,902	$ 41,968	$ 48,186

REVENUE, CREDIT CONCENTRATION_5

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Disaggregates of Total Net Product Revenues Based on Patient Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 505,344	$ 408,742	$ 1,558,501	$ 1,396,465
Product
Disaggregation of Revenue [Line Items]
Revenue	493,348	393,840	1,516,533	1,348,279
Marketed by Company | Total net product revenues marketed by the Company
Disaggregation of Revenue [Line Items]
Revenue	464,302	369,460	1,425,778	1,245,762
Marketed by Company | Total net product revenues marketed by the Company | United States
Disaggregation of Revenue [Line Items]
Revenue	176,552	166,554	497,205	491,028
Marketed by Company | Total net product revenues marketed by the Company | Europe
Disaggregation of Revenue [Line Items]
Revenue	162,583	108,568	480,645	424,144
Marketed by Company | Total net product revenues marketed by the Company | Latin America
Disaggregation of Revenue [Line Items]
Revenue	60,791	38,958	213,246	140,911
Marketed by Company | Total net product revenues marketed by the Company | Rest of world
Disaggregation of Revenue [Line Items]
Revenue	64,376	55,380	234,682	189,679
Marketed by Sanofi | ALDURAZYME net product revenues marketed by Sanofi
Disaggregation of Revenue [Line Items]
Revenue	$ 29,046	$ 24,380	$ 90,755	$ 102,517

REVENUE, CREDIT CONCENTRATION_6

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Total Net Product Revenue Concentrations Attributed to Largest Customers (Details) - Customer Concentration Risk - Net Product Revenue	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Customer A, B, & C
Concentration Risk [Line Items]
Concentration risk, percentage	39%	47%	37%	41%
Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	15%	20%	16%	17%
Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	14%	16%	12%	14%
Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	10%	11%	9%	10%

STOCK-BASED COMPENSATION - Expe

STOCK-BASED COMPENSATION - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 54,663	$ 49,026	$ 149,574	$ 153,372
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	4,361	4,339	13,449	16,907
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	17,055	17,866	47,878	56,199
Selling, general and administrative (SG&A)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 33,247	$ 26,821	$ 88,247	$ 80,266

NET INCOME PER COMMON SHARE - S

NET INCOME PER COMMON SHARE - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net Income (loss), basic	$ (6,652)	$ (36,494)	$ 141,810	$ (6,182)
Add: Interest expense, net of tax, on the 2024 Notes	0	0	2,806	0
Net Income (loss), diluted	$ (6,652)	$ (36,494)	$ 144,616	$ (6,182)
Denominator:
Weighted average common shares outstanding, basic (in shares)	185,597	183,214	185,009	182,616
Effect of dilutive securities:
Weighted average common shares outstanding, diluted (in shares)	185,597	183,214	192,252	182,616
Net income (loss) per common share, basic (in dollars per share)	$ (0.04)	$ (0.20)	$ 0.77	$ (0.03)
Net income (loss) per common share, diluted (in dollars per share)	$ (0.04)	$ (0.20)	$ 0.75	$ (0.03)
Issuances under equity incentive plans
Effect of dilutive securities:
Effect of dilutive securities (in shares)	0	0	3,273	0
Common stock issuable under the 2024 Notes
Effect of dilutive securities:
Effect of dilutive securities (in shares)	0	0	3,970	0

NET INCOME PER COMMON SHARE -_2

NET INCOME PER COMMON SHARE - Schedule Of Anti-Dilutive Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total number of potentially issuable shares (in shares)	20,556	21,055	13,313	21,055
Issuances under equity incentive plans
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total number of potentially issuable shares (in shares)	12,221	12,720	8,948	12,720
Common stock issuable under the Company's convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total number of potentially issuable shares (in shares)	8,335	8,335		8,335
Common stock issuable under the 2027 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total number of potentially issuable shares (in shares)			4,365

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2021	Jun. 30, 2020	Sep. 30, 2022
Commitments And Contingencies [Line Items]
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones			$ 777.6
Purchase commitments and other minimum contractual obligations			$ 171.5
Early Stage Development Program | Third Party
Commitments And Contingencies [Line Items]
Contingent payments upon achievement of certain development and regulatory activities and commercial sales and licensing milestones	$ 381.5	$ 225

SUBSEQUENT EVENT - (Details)

SUBSEQUENT EVENT - (Details) - 2022 Restructuring Plan $ in Millions		3 Months Ended
	Oct. 06, 2022 USD ($) employee	Sep. 30, 2022 USD ($)
Subsequent Event [Line Items]
Restructuring and related cost, incurred cost		$ 4.8
Subsequent Event
Subsequent Event [Line Items]
Restructuring and related cost, expected number of positions eliminated | employee	120
Percentage of workforce expected to be eliminated	4%
Minimum | Subsequent Event
Subsequent Event [Line Items]
Restructuring and related cost, expected cost	$ 20
Maximum | Subsequent Event
Subsequent Event [Line Items]
Restructuring and related cost, expected cost	$ 25